Now available TALVEY™

TALVEY™ (talquetamab-tgvs) injection, for subcutaneous use, is a bispecific GPRC5D-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Please see full prescribing information here.

PLEASE NOTE: To access these TALVEY products you must enroll and become certified in the TALVEY REMS.